DrugPatentWatch Database Preview
Fresenius Medcl Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for FRESENIUS MEDCL, and when can generic versions of FRESENIUS MEDCL drugs launch?
FRESENIUS MEDCL has nine approved drugs.
There are five US patents protecting FRESENIUS MEDCL drugs.
There are twenty-two patent family members on FRESENIUS MEDCL drugs in seventeen countries and seventy supplementary protection certificates in thirteen countries.
Summary for Fresenius Medcl
| International Patents: | 22 |
| US Patents: | 5 |
| Tradenames: | 22 |
| Ingredients: | 5 |
| NDAs: | 9 |
Drugs and US Patents for Fresenius Medcl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Medcl | CALCITRIOL | calcitriol | INJECTABLE;INJECTION | 075766-001 | Feb 20, 2003 | DISCN | No | No | Start Trial | Start Trial | |||||
| Fresenius Medcl | DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER | calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate | SOLUTION;INTRAPERITONEAL | 018883-004 | Nov 30, 1984 | AT | RX | No | No | Start Trial | Start Trial | ||||
| Fresenius Medcl | PHOSLO GELCAPS | calcium acetate | CAPSULE;ORAL | 021160-003 | Apr 2, 2001 | AB | RX | Yes | Yes | 6,875,445 | Start Trial | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Fresenius Medcl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Fresenius Medcl | PHOSLO | calcium acetate | TABLET;ORAL | 019976-001 | Dec 10, 1990 | 4,870,105 | Start Trial |
| Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-001 | Apr 2, 2001 | 4,870,105 | Start Trial |
| Fresenius Medcl | PHOSLO GELCAPS | calcium acetate | CAPSULE;ORAL | 021160-003 | Apr 2, 2001 | 4,870,105 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for FRESENIUS MEDCL drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 667 mg/5 mL | ➤ Subscribe | 2013-12-05 |
| ➤ Subscribe | Capsules | EQ 169 mg calcium | ➤ Subscribe | 2005-05-31 |
International Patents for Fresenius Medcl Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | PI0714882 | Start Trial |
| China | 104095838 | Start Trial |
| Japan | 5335674 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Fresenius Medcl Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2822954 | 18C1035 | France | Start Trial | PRODUCT NAME: BICTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER BICTEGRAVIR DE SODIUM; REGISTRATION NO/DATE: EU/1/18/1289 20180625 |
| 0145340 | 99C0005 | Belgium | Start Trial | PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204 |
| 1758590 | 2017C/063 | Belgium | Start Trial | PRODUCT NAME: SEL DE SODIUM D'ACIDE DESOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: SE/H/1547/01/DC 20170612 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
